Oxaliplatin Sensitizes OS Cells to TRAIL-induced Apoptosis Via Down-regulation of Mcl1

被引:6
作者
Huang, Tao [1 ]
Gong, Wei-Hua [2 ]
Li, Xiu-Cheng [1 ]
Zou, Chun-Ping [1 ]
Jiang, Guang-Jian [2 ]
Li, Xu-Hui [2 ]
Qian, Hao [1 ]
机构
[1] China Med Univ, Affiliated Hosp 1, Dept Orthoped, Shenyang, Liaoning, Peoples R China
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
关键词
Osteosarcoma; TRAIL; oxaliplatin; apoptosis; OSTEOSARCOMA CELLS; TARGETING MCL-1; UP-REGULATION; TUMOR-CELLS; EXPRESSION; COMBINATION; RESISTANCE; TOXICITY; LINES;
D O I
10.7314/APJCP.2012.13.7.3477
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the killing effect on OS cells of a combination of oxaliplatin and TRAIL and related molecular mechanisms. Methods: TRAIL and oxaliplatin were applied to OS732 cells singly or jointly and survival inhibition rates were measured by MTT assay, changes of cellular shape being assessed with inverted phase contrast and fluorescence microscopy. Apoptotic rates were analyzed by flow cytometry (FCM) and immunocytochemistry was used to examine Mcl1 expression of OS732 cells. Results: The survival inhibition rate of combined application of 100 mu g/ml TRAIL and 1 mu g/ml oxaliplatin on OS-732 cells was significantly higher than that of either agent singly (p<0.01). Changes of cellular shape and apoptotic rates also indicated apoptosis-inducing effects of combined application to be much stronger than those of individual application. Oxaliplatin had the effect of down-regulating Mcl1 expression and sensitizing OS cells to TRAIL-induced apoptosis. Conclusion: A combination of TRAIL and oxaliplatin exerts strong killing effects on OS-732 cells which might be related to down-regulation of Mcl1 expression.
引用
收藏
页码:3477 / 3481
页数:5
相关论文
共 28 条
  • [1] The antineoplastic antibiotic taurolidine promotes lung and liver metastasis in two syngeneic osteosarcoma mouse models and exhibits severe liver toxicity
    Arlt, Matthias J. E.
    Walters, Denise K.
    Banke, Ingo J.
    Steinmann, Patrick
    Puskas, Gabor J.
    Bertz, Josefine
    Rentsch, Katharina M.
    Ehrensperger, Felix
    Born, Walter
    Fuchs, Bruno
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (05) : E804 - E812
  • [2] A Phase II Trial and Pharmacokinetic Study of Oxaliplatin in Children With Refractory Solid Tumors: A Children's Oncology Group Study
    Beaty, Orren, III
    Berg, Stacey
    Blaney, Susan
    Malogolowkin, Marcio
    Krailo, Mark
    Knight, Ronald
    Schaiquevich, Paula
    Stewart, Clinton
    Chen, Zhengjia
    Nelson, Marvin
    Voss, Stephan
    Ivy, S. Percy
    Adamson, Peter C.
    [J]. PEDIATRIC BLOOD & CANCER, 2010, 55 (03) : 440 - 445
  • [3] Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy
    Bouralexis, S
    Findlay, DM
    Atkins, GJ
    Labrinidis, A
    Hay, S
    Evdokiou, A
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (01) : 206 - 214
  • [4] On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy
    Bruland, OS
    Pihl, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) : 1725 - 1731
  • [5] Brunat-Mentigny M, 1993, Rev Prat, V43, P2197
  • [6] Toxicity and anti-tumour efficacy of oxaliplatin on Glasgow Osteosarcoma in mice:: a mathematical model.
    Clairambault, J
    Claude, D
    Filipski, E
    Granda, T
    Lévi, F
    [J]. PATHOLOGIE BIOLOGIE, 2003, 51 (04): : 212 - 215
  • [7] Oxaliplatin Sensitizes Human Colon Cancer Cells to TRAIL Through JNK-Dependent Phosphorylation of Bcl-xL
    El Fajoui, Zineb
    Toscano, Florent
    Jacquemin, Guillaume
    Abello, Jacques
    Scoazec, Jean-Yves
    Micheau, Olivier
    Saurin, Jean-Christophe
    [J]. GASTROENTEROLOGY, 2011, 141 (02) : 663 - 673
  • [8] Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies
    Geoerger, Birgit
    Doz, Francois
    Gentet, Jean-Claude
    Mayer, Michele
    Landman-Parker, Judith
    Pichon, Fabienne
    Chastagner, Pascal
    Rubie, Herve
    Frappaz, Didier
    Le Bouil, Anne
    Gupta, Sunil
    Vassal, Gilles
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) : 4394 - 4400
  • [9] Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors
    Gores, Gregory J.
    Kaufmann, Scott H.
    [J]. GENES & DEVELOPMENT, 2012, 26 (04) : 305 - 311
  • [10] Oxaliplatin, Irinotecan, and Gemcitabine: A Novel Combination in the Therapy of Progressed, Relapsed, or Refractory Tumors in Children
    Hartmann, Carolin
    Weinel, Peter
    Schmid, Hansjoerg
    Grigull, Lorenz
    Sander, Anette
    Linderkamp, Christin
    Welte, Karl
    Reinhardt, Dirk
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2011, 33 (05) : 344 - 349